Lilly - Latest News and Investment Deals
LLY
Lilly is a medicine company turning science into healing to make life better for people around the world.
Baseline Debuts To Challenge GLP-1 Giant Lilly in Alcohol Use Disorder
5 FDA Decisions to Watch in the First Quarter of 2026
Keep an Eye on These 15 Biotech Companies in 2026
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
Roche Breast Cancer Prospect Fails First-Line Test, Shares Fall
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
Options Traders Pick Up Pharma Stock After Eli Lilly Buyout
Semaglutide Cuts Cardiac Risk 20% and Retatrutide Hits All Diabetes Endpoints
Trump's Obesity Drug Plan for Medicare Would Cost Insurers Billions
Novartis Breaks Ground on San Diego Biomedical R&D Site
Biotech in 2025: A Retrospective
Small And Mid-Sized Startup Purchases Are Still Well Below The 2021 Peak
Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact
Pfizer’s Early Metsera Data Leaves Analysts Wanting More
TerraPower Commits $450M to Build Radioisotope Production Plant
Breast Cancer Treatments Heat Up: Six Therapies Poised to Transform Patient Outcomes
Lilly’s GLP-1s Mounjaro, Zepbound Push Revenue up 46% in Q4
Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B
Tradipitant
FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain
Syremis Therapeutics Raises $165M in Series A Financing
Eli Lilly’s Retatrutide Targets Novo Nordisk’s GLP‑1 Stronghold with 28.7% Weight Loss Data
Deals Not Waiting for JPM
Vercel COO Discusses How AI Will Bolster Human Interactions in Sales
How Eli Lilly’s Biotech Collaboration Model Is Rewriting Early-Stage Innovation
The Next Generation of GLP-1 Drugs: And How They’ll Reshape Food and Beverage Again
Structure Therapeutics Reports More Phase 2 Data for Oral GLP-1
JPM26: Protagonist Has a $400M Decision To Make. It’s a No-Brainer
3 Trends Shaping the GLP-1 Landscape
Lilly Establishes up to $2.7B Repertoire Deal in Second Immune Play of 2026
Roche Raises NC Manufacturing Investment to $2B To Support Obesity Challenge
Sanegene Bio Closes Over $110 Million Series B
WHO Foundation, Novo Nordisk Collaborate on Childhood Obesity Prevention in India
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
Vanguard to Split Five Equity ETFs 5‑for‑1, Cutting MGK Share Price to ~$70
Bitcoin Makes Minor Gains Following Five Months of Losses
Bipartisan INSULIN Act Targets $35 Monthly Cap for Private‑Insurance Users
Trump Administration Sets up to 100% Tariffs on some Imported Drugs, with Many Companies Exempt
What We Still Don’t Know About Weight-Loss Drugs
A New Approach to Drugging MYC: The Application of Translation-Inhibiting Interdictors To MYC-Driven Malignancies
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
Novo Combination Obesity Shot Meets Goal in Diabetes Trial
STAT+: Insilico Medicine CEO on How Best to Use AI in Drug Development
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
11 Startups Selected for National Life Sciences Accelerator Program
Rhythm Surges On A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat'
GLP-1 Drugs Linked to Pancreatitis, Gallbladder Problems
The Benefits of an Immune-Directed ADC Strategy
Novo Nordisk Plans €432m Investment in Irish GLP-1 Plant
Politicization Runs Deeper than Ever at FDA, Risking Long-Term Impacts
Eli Lilly to Acquire Ventyx Biosciences for $1.2B
Gate Bioscience Secures $65M Series B Round Led by Forbion and Eli Lilly
QuantX Biosciences Secures $85M Series B Funding Led by Lilly and Sanofi Ventures
Eli Lilly Pays $100M for Rights to CSL’s Clazakizumab
Eli Lilly to Acquire Centessa Pharmaceuticals for $6.3B
Sanegene Bio Secures Over $110M in Series B Funding
Excelsior Sciences Secures $95M Series A Funding Led by Deerfield, Khosla and Sofinnova
Eli Lilly to Acquire Ventyx for $1.2B
Eli Lilly Commits $2.75B to Insilico Medicine for AI‑discovered Drug Candidates
Eli Lilly and Nvidia Sign Five‑year, up to $1 Billion AI Laboratory Deal
Eli Lilly to Acquire Orna Therapeutics for $2.4 Billion
